Advertisement

Ein modifiziertes Schema von 5-Fluorouracil (5-FU) mit Leucovorin (LV) mit guter Verträglichkeit

  • H. Denz
  • Ch. U. Ludwig
  • H. Gisin
  • J. P. Obrecht
Conference paper

Zusammenfassung

Die medikamentöse Behandlung metastasierter Tumoren des Gastrointestinaltraktes hat in den letzten Jahrzehnten nur wenig Fortschritte gemacht. Die Standardtherapie ist bisher eine Monotherapie mit dem fluorierten Pyrimidin 5-Fluorouracil (5-FU), dessen tumorhemmende Wirkung bereits 1957 beschrieben worden war [4].

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  1. 1.
    Einhorn LH (1989) Improvements in fluorouracil chemotherapy? J Clin Oncol 7: 1377–1379PubMedGoogle Scholar
  2. 2.
    Erlichmann C, Fine S, Wong A et al. (1988) A randomized trial of fluorouracil and folinic acid in patients with metastatic colorectal carcinoma. J Clin Oncol 6: 469–475Google Scholar
  3. 3.
    Evans RM, Laskin JD, Hakala MT (1981) Effect of excess folates and deoxyinosine on the activity and site of action of 5-fluorouracil. Cancer Res 41: 3288–3295PubMedGoogle Scholar
  4. 4.
    Heidelberger C, Chaudhari NK, Danneberg Petal. (1957) Fluorinated pyrimidine. A new class of tumor-inhibitory compounds. Nature 179: 663–666Google Scholar
  5. 5.
    Miller AB, Hoogstraten B, Staquet M et al. (1981) Reporting results of cancer treatment. Cancer 47: 207–214PubMedCrossRefGoogle Scholar
  6. 6.
    Nobile MT, Vidili MG, Sobrero A et al. (1988) 5-fluorouracil alone or combined with high dose folinic acid in advanced colorectal cancer patients: a randomized trial. Proc Amer Soc Clin Oncol 7: 97Google Scholar
  7. 7.
    Petrelli N, Douglass HO, Herrera L, Russell D et al. (1989) The modulation of fluorouracil with leucovorin in metastatic colorectal carcinoma: a prospective randomized phase III trial. J Clin Oncol 7: 1419–1426PubMedGoogle Scholar
  8. 8.
    Poon MA, O’Connell MJ, Moertel CG et al. (1989) Biochemical modulation of fluorouracil: evidence of significant improvement of survival and quality of life in patients with advanced colorectal carcinoma. J Clin Oncol 7: 1407–1418PubMedGoogle Scholar
  9. 9.
    Valone FH, Friedman MA, Wittlinger PS et al. (1989) Treatment of patients with advanced colorectal carcinomas with fluorouracil alone, high-dose leucovorin plus fluorouracil, or sequential methotrexate, fluorouracil, and leucovorin: a randomized trial of the northern california oncology group. J Clin Oncol 7: 1427–1436PubMedGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1992

Authors and Affiliations

  • H. Denz
  • Ch. U. Ludwig
  • H. Gisin
  • J. P. Obrecht

There are no affiliations available

Personalised recommendations